Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Assembly Biosciences Doses First Two Participants in Phase 2 Trial of Hepatitis Delta Drug ABI-6250

By Public Technologies
  • Assembly Biosciences dosed the first two participants in a Phase 2 trial of oral ABI-6250 for chronic hepatitis delta virus infection.
  • The trial targets approximately 80 participants, testing two once-daily doses for safety and antiviral activity.
  • Initial Phase 2 data are expected in the fourth quarter of 2027.
  • Phase 1a results supported further development, with a mean half-life of approximately four days supporting once-daily dosing.
  • Gilead holds an exclusive licensing option for ABI-6250 for $90 million through Phase 2 completion and review of the option data package.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291600PRIMZONEFULLFEED9856448) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.